

46. A pharmaceutical composition of claim 45 wherein the weight ratio of olanzapine to Drug Useful in the Treatment of Pain is about one (1) part olanzapine to about thirty (30) parts Drug Useful in the Treatment of Pain.

47. A pharmaceutical composition of claim 45 wherein the weight ratio of olanzapine to Drug Useful in the Treatment of Pain is about one (1) part olanzapine to about ten (10) parts Drug Useful in the Treatment of Pain.

48. A pharmaceutical composition of claim 45 wherein the weight ratio of olanzapine to Drug Useful in the Treatment of Pain is about one (1) part olanzapine to about three (3) parts Drug Useful in the Treatment of Pain.

49. A pharmaceutical composition of claim 45 wherein the Drug Useful in the Treatment of Pain is selected from the group consisting of Tylenol #3, tricyclic antidepressants (for example desipramine, imipramine, amitriptyline, nortriptyline), anticonvulsants (for example, carbamazepine, gabapentine, valproate), serotonin reuptake inhibitors (for example, fluoxetine, paroxetine, citalopram, sertraline), mixed serotonin-norepinephrine reuptake inhibitors (for example venlafaxine, duloxetine), serotonin receptor agonists and antagonists, cholinergic (muscarinic and nicotinic) analgesics, and neurokinin antagonists.

50. A pharmaceutical composition of claim 49 wherein the Drug Useful in the Treatment of Pain is Tylenol #3.

51. A pharmaceutical composition of claim 49 wherein the Drug Useful in the Treatment of Pain is a tricyclic antidepressant.

52. A pharmaceutical composition of claim 51 wherein the tricyclic antidepressant is desipramine.

53. A pharmaceutical composition of claim 51 wherein the tricyclic antidepressant is imipramine.

54. A pharmaceutical composition of claim 51 wherein the tricyclic antidepressant is amitriptyline.

55. A pharmaceutical composition of claim 51 wherein the tricyclic antidepressant is nortriptyline.

56. A pharmaceutical composition of claim 49 wherein the Drug Useful in the Treatment of Pain is an anticonvulsant.

57. A pharmaceutical composition of claim 56 wherein the anticonvulsant is carbamazepine.

58. A pharmaceutical composition of claim 56 wherein the anticonvulsant is gabapentine.

59. A pharmaceutical composition of claim 56 wherein the anticonvulsant is valproate.

60. A pharmaceutical composition of claim 49 wherein the Drug Useful in the Treatment of Pain is a serotonin reuptake inhibitor.

61. A pharmaceutical composition of claim 60 wherein the serotonin reuptake inhibitor is fluoxetine.

62. A pharmaceutical composition of claim 60 wherein the serotonin reuptake inhibitor is paroxetine.

63. A pharmaceutical composition of claim 60 wherein the serotonin reuptake inhibitor is citalopram.

64. A pharmaceutical composition of claim 60 wherein the serotonin reuptake inhibitor is sertraline.

65. A pharmaceutical composition of claim 49 wherein the Drug Useful in the Treatment of Pain is a mixed serotonin-norepinephrine reuptake inhibitor.

66. A pharmaceutical composition of claim 65 wherein the mixed serotonin-norepinephrine reuptake inhibitor is venlafaxine.

67. A pharmaceutical composition of claim 65 wherein the mixed serotonin-norepinephrine reuptake inhibitor is duloxetine.

68. A pharmaceutical composition of claim 49 wherein the composition is associated with a pharmaceutically acceptable excipient.

69. A pharmaceutical composition of claim 68 wherein the composition is enclosed within a carrier.

70. A pharmaceutical composition in unit dose form comprising olanzapine or a pharmaceutically acceptable salt or solvate thereof; and a Drug selected from the group consisting of Tylenol #3, tricyclic antidepressants (for example desipramine, imipramine, amitriptyline, nortriptyline), anticonvulsants (for example, carbamazepine, gabapentine, valproate), serotonin reuptake inhibitors (for example, fluoxetine, paroxetine, citalopram, sertraline), mixed serotonin-norepinephrine reuptake inhibitors (for example venlafaxine, duloxetine), serotonin receptor agonists and antagonists, cholinergic (muscarinic and nicotinic) analgesics, and neurokinin antagonists wherein the weight ratio of olanzapine to compound is about one (1) part olanzapine to about ten (10) parts compound.

71. A pharmaceutical composition in unit dose form of claim 70 wherein the Drug is Tylenol #3.

72. A pharmaceutical composition in unit dose form of claim 70 wherein the Drug is a tricyclic antidepressant.

73. A pharmaceutical composition in unit dose form of claim 72 wherein the tricyclic antidepressant is desipramine.

74. A pharmaceutical composition in unit dose form of claim 72 wherein the tricyclic antidepressant is imipramine.

75. A pharmaceutical composition in unit dose form of claim 72 wherein the tricyclic antidepressant is amitriptyline.

76. A pharmaceutical composition in unit dose form of claim 72 wherein the tricyclic antidepressant is nortriptyline.

77. A pharmaceutical composition in unit dose form of claim 70 wherein the Drug is an anticonvulsant.

78. A pharmaceutical composition in unit dose form of claim 77 wherein the anticonvulsant is carbamazepine.

79. A pharmaceutical composition in unit dose form of claim 77 wherein the anticonvulsant is gabapentine.

80. A pharmaceutical composition in unit dose form of claim 77 wherein the anticonvulsant is valproate.

81. A pharmaceutical composition in unit dose form of claim 70 wherein the Drug is a serotonin reuptake inhibitor.

82. A pharmaceutical composition in unit dose form of claim 81 wherein the serotonin reuptake inhibitor is fluoxetine.

83. A pharmaceutical composition in unit dose form of claim 81 wherein the serotonin reuptake inhibitor is paroxetine.

84. A pharmaceutical composition in unit dose form of claim 81 wherein the serotonin reuptake inhibitor is citalopram.

85. A pharmaceutical composition in unit dose form of claim 81 wherein the serotonin reuptake inhibitor is sertraline.

86. A pharmaceutical composition in unit dose form of claim 70 wherein the Drug is a mixed serotonin-norepinephrine reuptake inhibitor.

87. A pharmaceutical composition in unit dose form of claim 86 wherein the mixed serotonin-norepinephrine reuptake inhibitor is venlafaxine.

88. A pharmaceutical composition in unit dose form of claim 86 wherein the mixed serotonin-norepinephrine reuptake inhibitor is duloxetine.